Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...

HEOR scientists in the pharma industry must balance methodologic rigor with commercial expectations and timelines.

Self-service data analytics company Gigasheet announced a new digital platform designed to enhance healthcare price ...

The approval of neffy marks the first major advancement in epinephrine delivery for patients over four years of age in more ...

The acquisition is expected to enhance Jazz's oncology portfolio by adding dordaviprone, a novel small molecule therapy in ...

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, explores what kind of role ...

Joint venture is expected to leverage Astellas' expertise in cell therapy R&D and Yaskawa’s robotics technology to enhance ...

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, describes how his company's ...

In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...

In this Pharmaceutical Executive Video Interview, Peter Ax, Founder & CEO of UpScriptHealth, explores how tariffs could ...

The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...